Executive Profile:/ J&J Benelux Director Heads to Iberia
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
The Royal Academy of Medicine began its history in the first third of the eighteenth century in the midst of a gathering in the pharmacy of José Hortega, under the Enlightenment movement. In July 1733 it became a grouping of professionals, initially titled “Tertulia Médico-Chymica-Phisica” and later “Tertulia Médica Matritense”.
It received the royal sanction from Felipe V in September 18, 1734, following approval of its statutes, which became the Tertulia in Academia.
It was reorganized by Royal Decree of April 28, 1861, “to promote the progress of Spanish medicine, publish its story literature, forming the medical geography and a technological dictionary of medicine.”
It uses as emblem a shield that represents the allegory of Archimedes, which states that by using many small mirrors arranged in a dish and using the sun’s rays, set the Roman fleet on fire.
The academic medals bear a midwife allegory symbolizing medicine and the legend “Ars cum natura ad salutem conspirans”.
Today, the Royal Academy of Medicine holds public scientific sessions every Tuesday during the course, in which two scholars set scientific issues, takeover sessions, opening and closing of the course, special sessions, etc.
Regarding publications, the journal published quarterly RANM Annals, which includes the lectures delivered at scientific sessions, news bulletins, an activity newsletter and monographs, etc…
The tasks and current projects of the Royal Academy include: the Dictionary of Medical Terms, the announcement and awarding of prizes, computerization of its bibliography, etc.
It consists of fifty Academic Fellows and Honor Scholars, Corresponding National and Foreign Fees and Medals of Honor.
Its current President, since 2012, is Prof. D. Joaquin Poch Broto.
CONTACT DETAILS
Calle Arrieta nº12
28013 Madrid
Tlf.: +34 91 547 03 18
Fax: +34 91 547 03 20
Brazilian national Maria Fernanda Prado, who began her career in pharma more than 20 years ago, has been at Janssen/Johnson & Johnson for more than half of that time. She…
Thanks to what AstraZeneca country president Rick Suarez called a “thriving life-science eco-system and highly-skilled talent pool,” along with Spain’s leading position in clinical trials, the British Big Pharma is…
Having forged a solid position in clinical research in 2020 and 2021 when it became the fourth nation in the world and the first in Europe for studies conducted around…
The European Union’s just-released and first essential medicines list is the latest in a series of measures designed to limit the bloc’s reliance on countries outside its borders and avoid…
The COVID-19 pandemic and subsequent shortages of essential medicines and APIs laid bare Europe’s reliance on suppliers outside its borders. To combat this issue and ensure that Europe is better…
A roundup of the latest news from Spanish pharma, including Almirall’s licensing deal with EpimAb Biotherapeutics; the opening of Insud Pharma’s oligonucleotides centre in India, and Esteve Química’s new FDA-cleared…
Spanish mid-cap Esteve is selling a 26 percent stake in the company to German private investment firm Lubea, a move it says will supply the necessary funds to further pursue…
The latest news from Spanish pharmaceuticals and healthcare, including national champion Esteve’s decision to sell of a quarter of its stock to German private investment firm Lubea; news of pharma’s…
A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment…
The grants and loans allocated by the European Union’s Recovery and Resilience Facility (RRF), a large part of which have been assigned to healthcare, set out to mitigate the economic…
What major regulatory trends are emerging in Europe and in Spain? As one of the founding partners of a law firm focused uniquely on the life sciences industry, Faus &…
Faus & Moliner Abogados is a Spanish law firm that has been specializing in pharma and life sciences law since 1997. Founding partner Jordi Faus explains how having a comprehensive…
See our Cookie Privacy Policy Here